Navigation Links
ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
Date:5/13/2008

ion. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated several clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN(R), a specific CCR9 antagonist, is currently in a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. CCX140, which targets the CCR2 receptor, is currently in Phase I and may subsequently be developed for diseases such as vascular restenosis, Type 2 diabetes and/or multiple sclerosis, and CCX354, a CCR1 antagonist in Phase I, is being developed for inflammatory diseases such as rheumatoid arthritis. ChemoCentryx is privately held. For more information, please refer to http://www.chemocentryx.com.

Any statements in this press release about ChemoCentryx's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as may, believe, will, expect, anticipate, estimate, intend, predict, seek, potential, continue, plan, should, could and would or the negative of these terms or other comparable terminology. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the initiation
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Go Healthy Initiates Additional Clinical Tests on Cholesterade
2. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
5. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
8. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
9. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/r6wspz/drug_delivery_in ... new report "Drug Delivery in Central Nervous ... to their offering. Advances in ... have opened new avenues and possibilities for improved ... transport systems, enzymes, and receptors that control the ...
(Date:9/2/2015)... Demers Ambulances is proud to announce it has signed Emergency ... states of Mississippi , Alabama ... "This will enable Demers to effectively meet the needs ... for Demers Ambulances. "Emergency Equipment Professionals has three service centers ... Alabama , giving them a strategic advantage. Local service ...
(Date:9/2/2015)... Sept. 2, 2015  MiMedx Group, Inc. (NASDAQ: ... human amniotic tissue and patent-protected processes to develop ... Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic ... inaccurate statements published by the Musculoskeletal Transplant Foundation ... 2015. MTF,s September 1st press release ...
Breaking Medicine Technology:Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3Demers Ambulances has named Emergency Equipment Professionals (EEP) Inc. as their dealer for the states of MS, AL and TN 2MiMedx Corrects A Second Inaccurate MTF Press Release 2MiMedx Corrects A Second Inaccurate MTF Press Release 3
... BEACH, Fla., Nov. 7 Most patients with hereditary ... HAE attack giving the patients sufficient time to initiate ... according to survey findings presented today at the 2009 ... Meeting. Early recognition of symptoms such as fatigue and ...
... DUSA Pharmaceuticals, Inc.(®) (Nasdaq GM: DUSA), a dermatology ... (PDT) and other products focused on patients with common ... Executive Officer, will present a corporate overview at the ... 10, 2009 at 10:00 a.m. ET at the Hotel ...
Cached Medicine Technology:Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity 2Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity 3
(Date:9/2/2015)... ... ... A recent survey by Consumer Reports ( http://bit.ly/1h67tL8 ) sheds light on ... consumers. It was reported that 33% are paying an average of $39 more out-of-pocket ... $100 compared to last year. Among the drugs that saw the highest increases were ...
(Date:9/2/2015)... ... September 02, 2015 , ... World ... Free Pocket Cop, a safety invention that protects people from crime and other ... billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing. "The ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... SERVICE GROUP is internationally known as an industry leader specializing in surplus used ... world, selling more than 100,000 pieces of medical equipment every year. Erik Tivin, ...
(Date:9/2/2015)... ... September 02, 2015 , ... Ovarian cancer continues to ... woman’s risk of getting ovarian cancer in her lifetime is approximately 1 in 75. ... of ovarian cancer, and 14,000 will die. , There is no test to ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... to bring awareness to International Overdose Awareness Day. The goal is to provide ... the warning signs so that they may get help. , Lakeview ...
Breaking Medicine News(10 mins):Health News:Watertree Health President Responds to Consumer Reports Survey on Rising Prescription Drug Prices 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 4Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 5Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 6Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 7Health News:Over 1800 Lots of Surplus Used Medical Equipment 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 3Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 3Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2
... Alcohol Provides Parents Resources to Help Manage Teen ... Access to Alcohol in the ... Alcohol today challenged New York area parents to take a tough,topic ... a roundtable discussion featuring a panel of experts from the fields,of ...
... to a study using a dynamic in vitro gastrointestinal ... SHQ) ulcerative colitis drug LIALDA (mesalamine) demonstrated a delivery ... 5-aminosalicyclic acid (5-ASA), is released over a prolonged period ... site of inflammation in ulcerative colitis. In this in ...
... any more sensitive in detecting biological motion compared with ... of Vision, an online, free-access publication of the Association ... Eric Hiris of St. Mary,s College of Maryland, (St ... on the subject begin with statements to the effect ...
... employee assistance,division of Recovery Resources Inc., is offering ... of October in,recognition of national Drug-Free Work Week ... an effective drug free workplace program. The ... 2007" in an,effort to educate businesses about the ...
... - With Photo - Business Executives Encouraged to ... Stroke and Funds for the Stroke Association Tom ... Olympic gold medallist, today launched ,Siemens Stroke for Stroke,Week, ... to,highlight the positive benefits of regular exercise and to ...
... New benefit offered to 10,000 Medicare Choice PPO members at no additional ... ... YORK, Oct. 17 Effective January 1, 2008, Group,Health Incorporated (GHI) has ... call a toll-free number to speak with,their own independent Personal Health Advocate ...
Cached Medicine News:Health News:Parents Encouraged to Set an Example for Their Teens and Help Stop Underage Drinking 2Health News:Parents Encouraged to Set an Example for Their Teens and Help Stop Underage Drinking 3Health News:Parents Encouraged to Set an Example for Their Teens and Help Stop Underage Drinking 4Health News:Parents Encouraged to Set an Example for Their Teens and Help Stop Underage Drinking 5Health News:LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon 2Health News:LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon 3Health News:AssistNow Offers Area Employers Complimentary Needs Assessment in Recognition of National Drug-Free Work Week 2Health News:James Cracknell Launches Siemens Stroke for Stroke Week 2Health News:James Cracknell Launches Siemens Stroke for Stroke Week 3Health News:James Cracknell Launches Siemens Stroke for Stroke Week 4Health News:GHI to Provide Independent Personal Health Advocate for Medicare Members 2
The ImagingPlanet 80 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 80 mm focal length adapter an excellent decision for use with your Zeiss surgical micro...
The ImagingPlanet 55 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Zeiss surgical micro...
The ImagingPlanet 70 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Leica surgical micr...
... Archive Manage and ... ,Introducing Optronics DVMR- office, the ... designed for the physician's office ... a variety of high-resolution cameras ...
Medicine Products: